56180-94-0
Chemical Structure
Acarbose
Synonym(s): BAY g 5421
- CAS No.: 56180-94-0
- Formula:C25H43NO18
- Molecular Weight:645.60
IUPAC Name: (2R,3R,4R,5R)-4-(((2R,3R,4R,5S,6R)-5-(((2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-(((1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl)amino)tetrahydro-2H-pyran-2-yl)oxy)-3,4-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-2,3,5,6-tetrahydroxyhexanal
InChIKey: CEMXHAPUFJOOSV-XGWNLRGSSA-N
SMILES: OC[C@H]([C@]1(O[C@@H]2[C@H](O)[C@@H](O)[C@@H]([C@H](O2)C)N[C@]3(C=C(CO)[C@H]([C@@H]([C@H]3O)O)O)[H])[H])O[C@@H]([C@@H]([C@H]1O)O)O[C@@]([H])([C@@H]([C@H](C=O)O)O)[C@@H](CO)O
Biological Activity: Acarbose (BAY g 5421), antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC50=11 nM). Acarbose can potentiate the hypoglycemic effects of sulfonylureas or insulin[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Acarbose | 99.97% | Acarbose (BAY g 5421), antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC50=11 nM). Acarbose can potentiate the hypoglycemic effects of sulfonylureas or insulin. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Acarbose (Standard) | 99.93% | Acarbose (Standard) is the analytical standard of Acarbose. This product is intended for research and analytical applications. Acarbose (BAY g 5421), antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC50=11 nM). Acarbose can potentiate the hypoglycemic effects of sulfonylureas or insulin. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Acarbose-d4 | Acarbose-d4 (BAY g 5421-d4) is deuterium labeled Acarbose. Acarbose (BAY g 5421), antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC50=11 nM). Acarbose can potentiate the hypoglycemic effects of sulfonylureas or insulin. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Yee HS, et al. A review of the safety and efficacy of acarbose in diabetes mellitus. Pharmacotherapy. 1996;16(5):792-805. [Content Brief]
- [2]. Hanefeld M, et al. Acarbose: oral anti-diabetes drug with additional cardiovascular benefits [published correction appears in Expert Rev Cardiovasc Ther. 2009 Mar;7(3):330]. Expert Rev Cardiovasc Ther. 2008;6(2):153-163. [Content Brief]
- [3]. Oki T, et al. Evaluation of alpha-glucosidase inhibition by using an immobilized assay system. Biol Pharm Bull. 2000;23(9):1084-1087. [Content Brief]
